Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Thermo Fisher Scientific Inc | NYSE:TMO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 514.20 | 0 | 00:00:00 |
From Nov 2023 to Nov 2024
By Ben Glickman
Galapagos said it had entered an agreement with Thermo Fisher Scientific to expand manufacturing of its immune-cell cancer treatment candidate.
The company said that Thermo Fisher had agreed to provide CAR-T manufacturing and kitting services for Galapagos' CAR-T hemato-oncology clinical program in the San Francisco area.
Galapagos in November signed a deal with Landmark Bio to manufacture CAR-T in the Boston area.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 04, 2024 16:29 ET (21:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Thermo Fisher Scientific Chart |
1 Month Thermo Fisher Scientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
